[PRNewswire] Jemincare Announces Exclusive License Agreement with Genentech to
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Develop and Commercialize Novel Oral Androgen Receptor Degrader
(SHANGHAI, Aug. 18, 2022 PRNewswire=연합뉴스) Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.
Under the terms of the agreement, Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs. In return, Genentech will pay Jemincare a USD 60 million upfront payment. Jemincare is also entitled to receive up to USD 590 million in additional payments upon achievement of certain development, regulatory and sales-based milestone targets. Jemincare is also entitled to receive tiered royalties on net sales.
JMKX002992 is a novel oral degrader of the androgen receptor, a confirmed disease driver in prostate cancer. JMKX002992 has the potential to treat patients with prostate cancer who have developed resistance to current therapies.
"We are delighted to enter into collaboration with Roche, one of the world's leading pharmaceutical companies providing transformative innovative solutions across major disease areas, and Genentech, a worldwide leading innovator in oncology. We trust this partnership could significantly enhance and accelerate the development and potential commercialization of JMKX002992 to benefit patients. This is our third innovative therapy partnered globally. We are proud of this achievement within only four years since the establishment of our R&D center. Jemincare will continue to realize our commitment to benefit patients with innovative solutions." said Mr. Hong Liang, President of Jemincare Pharmaceutical Group.
"Prostate cancer remains a leading cause of death in men worldwide," said James Sabry, Global Head of Roche Pharma Partnering. "Certain forms of prostate cancer can be particularly difficult to treat. Jemincare's novel oral androgen receptor degrader will complement our efforts to develop new treatment options for patients with advanced prostate cancer."
About Jemincare
Jiangxi Jemincare Group Co., Ltd. is a leading pharmaceutical company from China. Founded in 1999, Jemincare is mainly engaged in pharmaceutical industry. The company is dedicated to the development, manufacturing and commercialization of therapeutics in its strategic fields including oncology, nephrology, cerebro-cardiovascular, anti-infection, analgesic, respiratory and Pediatrics. Shanghai Jemincare Pharmaceutical Co., Ltd is the R&D center of Jiangxi Jemincare Group Co., Ltd. Shanghai Jemincare has developed a strong team with around 500 scientists comprised by 3 innovation centers, Small Molecule Innovative Center, Biologics Innovation Center and Technology Innovation Center. The androgen receptor degrader program was developed by the Small Molecule Innovation Center which had more than 10 programs entering IND or IND-enabling stage and 3 programs entering clinical stage. For more information, please visit www.jemincare.com
Source: Jemincare
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 어린이날 제주 한라산 900㎜ 물폭탄…항공편 결항 속출(종합2보) | 연합뉴스
- "비 와도 신나요" 어린이날 실내 행사장 '북적'(종합) | 연합뉴스
- 복지부, 의대 증원 논의한 보정심 회의록, 10일까지 법원에 제출 | 연합뉴스
- 네타냐후 "일시휴전 할 수 있지만 종전은 수용 못해" | 연합뉴스
- 여야 원내지도부 재정비…22대 국회 길목서 특검 대치(종합) | 연합뉴스
- 정부24에서 타인 민원서류 발급…개인정보위 조사 착수(종합) | 연합뉴스
- [삶-특집] "딸, 제발 어디에 있니?"…한겨울에도 난방 안 하는 부모들(종합) | 연합뉴스
- 프로농구 KCC, 정규리그 5위 최초 챔프전 우승…MVP 허웅(종합2보) | 연합뉴스
- "과채 가격도 부담"…1년 전보다 방울토마토 42%·참외 36% 올라 | 연합뉴스
- 與 원내대표 이종배·추경호·송석준 '3파전'…이철규는 불출마(종합2보) | 연합뉴스